Methods for reducing pain and drug delivery devices

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, and may be used in treating the patients suffering headaches and facial pains. There are presented versions of a drug delivery device comprising an injector a first end of which is left outside patient's nasal passages. Another end of the injector comprises one or more holes for spraying a drug upwards, and/or to the side, and/or to the front towards a sphenopalatine ganglion, an input device interacting with a patient's nostril and comprising a canal for receiving the injector. Additionally, the device can comprise a handle connected to the input device and provided for receiving the canal of the input device. The injector can move between a storage position before the interaction, and an interaction position related to the interaction. There are also presented versions of the method of using the above device that involve introducing the injector through the nasal passage into median and/or posterior and/or inferior region in relation to the patient's sphenopalatine ganglion, and spraying the drug.

EFFECT: group of inventions provides faster and more effective headache and facial pain relief by safe and accurate drug delivery of the therapeutic substances blocking the sphenopalatine ganglion.

49 cl, 4 dwg, 30 ex

 

The group of inventions described herein, refers, essentially, to devices and methods for delivery of drugs, in particular, though not exclusively, to the introduction of drugs to control the pain associated with headaches, facial pain, etc.

Conventional methods for treatment of pain associated with headaches and facial pain, not as safe and effective as is desirable. For example, nonsteroidal anti-inflammatory drugs (NSAID), such as brand drugs SOH-2, should be used rarely and not long-term because they can cause ulcers and heart attacks - deficiency, which is then accompanied by inefficiency effects of these drugs on a large number of patients. The drug is also not recommended because of their ability to cause dependence. Additionally, the use of drugs on the basis of tryptamine, which include, but are not limited to, sumatriptan (marketed under the trade name IMITREX F. GlaxoSmithKline), and zolmitriptan (marketed under the trade name ZOMIG F. AstroZeneca), is undesirable because of the high cost and potentially high toxicity of these drugs.

One method used to control pain associated with headaches and facial pain, known as ONG blockade. In this case, anest the tick is applied to basic-sphenopalatine ganglion (ONG) of the patient by a trained health worker, which usually enters the applicator with a cotton tip soaked with anesthetic, into the nostril of the patient with the aim of applying anesthetic to ONG. Using the average nasal sink as anatomical landmark moistened applicators with a cotton end pushed up, essentially, blind (successful implementation depends largely on the qualifications and experience of the physician). It is clear that the efficacy and safety of this procedure leaves much to be desired. In addition, the efficacy and safety of conventional ONG blockade significantly reduced in the long-existing but erroneous belief, widespread among doctors that ONG is located behind the upper turbinate, which is not the case.

The scope of invention is defined solely by the attached claims and not limited in any way by the claims set forth in this brief description.

The first method of relieving pain in a patient provides for the introduction of the injector through the nasal passage of the patient in the region, essentially, medium, and/or back and/or lower relative to the primary nebnom the ganglion of the patient and the injection of medication through the injector up and/or sideways, and/or toward the primary nebnom the ganglion.

The first device for delivery of medication to a patient in need this contains (a) an injector comprising and the first end, designed in such a way that it remained outside the nasal passage of the patient, and the second end is designed in such a way that it has entered into a nasal passage of a patient; and (b) an input device is designed in such a way that it interacted with the nostrils of a patient and includes a bypass passage for receiving the injector slidable.

A second device for delivery of medication to a patient in need this contains (a) an injector containing the first end, made to stay outside nasal passage of a patient, a second end, is made to enter into the nasal passage of a patient, and a bypass channel that extends from the first end to the second end and is made so that it could enter a drug, where the second end of the injector contains one or multiple holes made for spraying the medication upwards, sideways and forward in the direction of the main-nebnom the ganglion; (b) an input device made to interact with the nostrils of the patient and containing a passage for receiving slidable injector, the first portion having such a shape that corresponds to the inner part of the nostrils, and the second section containing rounded convex section and an essentially flat back side, where the area of the cross the first section of the first section more than the cross-sectional area of the second segment; and (C) a handle connected to the input device and includes a guiding device (the guide), is designed to accommodate the bypass channel input devices. The handle is designed so that it can move in the direction of the patient's face so that movement of the handle back the input device is operated in cooperation with the nostrils of the patient. The injector is able to move between the storage position prior to the interaction, and the position of the interaction in accordance with the interaction, in which the position of the interaction is in the middle, behind and below the main-Palatine ganglion.

The second method of relieving pain in a patient provides for delivery of drug to the upward and/or sideways, and/or toward the primary nebnom the ganglion using the described device.

BRIEF DESCRIPTION of DRAWINGS

Figure 1 is a side view in cross section of a device for delivery of medication to a patient in need this to enter your device into the nostril of the patient, in accordance with the described principles.

Figure 2 is a top view in section of the device shown in figure 1, along line 2-2.

Figure 3 is a side view in section of the device shown in figure 1, after the input device has entered into cooperation with nasdr the th patient in accordance with the described principles.

Figure 4 is a side view in section of the device shown in figure 1, after the input device has entered into cooperation with the nostrils of the patient and after the injector was moved from the storage position to the position of the interaction, as a result, the second end of the injector is set up, sideways and forward relative to the main-nebnom the ganglion.

Figure 5 is a view in cross section of a human head in the midline, where ONG 2 is shown in the correct anatomical position behind the middle turbinate 4.

Description of the INVENTION

Here are presented and described a previously unknown and highly effective methods of relieving pain in a patient, essentially, but not exclusively, headaches, facial pain and such, and convenient device that allows easy management of medicines in accordance with these methods. As shown below, the described methods and devices allow you to apply the medication up and/or sideways, and/or toward the primary nebnom the ganglion of the region, essentially located in the middle of and/or behind and/or below basic-Palatine ganglion. The methods and devices can provide the patient and the doctor a safe and effective way to create ONG blockade, essentially, that can be used by the physician and/or directly by the patient without assistance or guidance qualified the new medical staff.

It is assumed that used here, the phrase "towards the primary nebnom the ganglion" and similar phrases used in relation to the delivery of the drug include himself ONG, and pterygopalatine fossa, which is ONG and major Palatine foramen.

As an introduction figure 5 shows a view in cross section of a human head in the midline, which correctly identified the location ONG 2, behind the middle turbinate 4, not behind the anterior turbinate 6 or top 8 of the nasal cavity near the ethmoid plate of the ethmoid bone 9, as mistakenly believed by many doctors. In addition, the correct location ONG 2 actually displaced laterally from the plane of the drawing, in other words, ONG is not in a two-dimensional plane is a cross-section, as well as erroneously believed by many doctors.

In U.S. Patent US No. 4,886,493, Jordan Yee describes the process ONG blockade, in which the tube is inserted in a nostril of the patient for delivering drugs to the pterygopalatine fossa, which is ONG. Unfortunately, as shown in Figure 3 of U.S. Patent US No. 4,886,493, the location of the pterygopalatine fossa (18) was incorrectly identified as being behind the upper turbinate and x-y - plane, available in a straight line from the nostrils through the tube (11). As a result of this wrong is about understanding, in addition to the expected decrease in efficiency, which may result from the delivery of the drug are not to the right place, end (13) of the device Yee passes dangerously close to the weak lattice plate of the ethmoid bone. Since the lattice plate ethmoid bone resembles a sieve and is in communication with the frontal lobes of the brain, it is extremely dangerous to enter anesthetics in the immediate vicinity of this record, as they can easily penetrate the frontal lobe.

In U.S. Patent US No. 6,491,940, ed. Bruce Levin, described an alternative procedure to perform ONG blockade. Unlike patent Yee described above, U.S. patent US No. 6,491,940 B1 recognizes lateral displacement ONG, because it describes a curved rather than straight body (100), where does the anesthetic. Unfortunately, as the patent Yee, patent Levin refuses to acknowledge that the correct location ONG - behind the middle turbinate, and not at the apex of the nasal cavity, as shown in Figa patent Levin and as described there (for example, paragraph 72, lines 20-22). Thus, as in the case of Patent Yee, the process described in the patent Levin, again makes the device delivery of anesthetic in dangerous proximity lattice plate of the ethmoid bone with all the possible risks and the associated loss of efficiency.

In U.S. Patent US the 6,322,542 B1, received at AstraZeneca, describes a device for delivering medication into the nasal cavity of the patient. Although the task of this invention is the efficient delivery of medication in the posterior region of the nasal cavity (paragraph 1, lines 29-32), its configuration (for example, the linearity of the tubular element 35) poorly adapted for delivery of medication to or in close proximity to ONG. Rather, the drug is being submitted in region 7 shown in Figure 5 of the present description. Delivery of anesthetics in close proximity to area 7 is extremely undesirable, since, as anesthetics can easily suppress the gag reflex, creates the risk of aspiration pneumonia. At the same time, not wishing to be bound by any particular theory nor intending to affect in any way the essence of the claims of the invention or its equivalents, the following background information provides a relatively modern understanding of anatomy ONG in order to further clarify the description of the proposed devices and methods.

ONG (also known as the pterygopalatine ganglion) is the largest group of neurons on the outer side of the cranial cavity and is located in the pterygopalatine fossa, the dimensions of which are approximately 1 cm wide and about 2 cm in height. The pterygopalatine fossa is limited in front of the rear walls of the Oh of the maxillary sinus, behind - the average plate of the pterygoid process, in the middle of the perpendicular plate of Palatine bone and ahead of the sphenoid sinus. The side of the pterygopalatine fossa communicates with the apex of the fossa (significanoe hole).

ONG inside the pit is located behind the middle turbinate and juts out a few millimeters (1 to 5 mm) into the side of the nasal mucosa. ONG has a complex nerve center and lots of links (connections). ONG is separated from the maxillary branch of the trigeminal nerve in the pterygopalatine fossa and pterygopalatine nerves and is located in the middle of the maxillary branch when viewed in sagitally plane. Rear ONG connects to the nerve of the pterygoid canal (medievil nerve). Himself ONG has exhaust branches and forms a top, rear, lateral nasal and pharyngeal nerves. In the rear part of the ganglion (ONG) is in direct connection with larger or smaller nebnymi nerves.

ONG has nerve, motor and autonomic components (elements). Nerve fibers are raised from the maxillary nerve, pass through ONG and are distributed to the nasal membranes, soft palate and some parts of the pharynx.

It is also considered that a number of motor nerve enters the nerve trunks. Autonomic innervation ONG more complex. The sympathetic component (e is ement) begins with preganglionarnah sympathetic fibers, coming from the upper part of thoracic spinal cord, forming white connective branches, passing through the sympathetic ganglia, where preganglionarnah fibers form a synapse (connect) with postganglionarnyh fibers. Postganglionarnyh fiber is then attached to the nerves in the carotid artery to the bifurcation and passing through the deep petrosal nerve and the nerve of the pterygoid canal. Postganglionic nerves pass through ONG on the way to the lacrimal glands and the mucous membrane of the nose and palate.

ONG is usually considered parasympathetic functions. The parasympathetic component (element) ONG has its preganglionarnah origin in the upper stimulating salivation centers, then passes through the area of the facial nerve (VII) prior to the formation of the greater petrosal nerve to form the nerve of the pterygoid canal, which ends at ONG. Inside ONG preganglionarnah fiber connect (create synapsis) with their postganglionarnye cells and continue on the mucous membrane of the nose, and one branch is in conjunction with the maxillary nerve to the lacrimal gland.

Despite the above description and regardless of current theories concerning the anatomy ONG, resulting from the use of the devices and methods described below can be achieved be the dangerous and effective pain relief. Although the exemplary device 10 will be described with reference to Figures 1 to 4, it should be understood that this exemplary device is merely illustrative and alternative constructions may likewise be used for delivery of medication in accordance with the principles described here. It should be understood that the elements and details of the various exemplary devices described below may be combined in various ways with the aim of producing new variants that also applies to the scope of this teaching. The drawings and the description below is presented only as illustrations and are not intended to limit the scope of the claims, or equivalents.

Figure 1-4 shows an exemplary device 10 for delivering medication to a patient who needs it. The device 10 includes an injector 12 includes a first end 29, is made so as to remain outside the nasal passage of a patient, and a second end 30, is made to enter into the nasal passage of the patient. The device 10 further contains input unit 18, made with the ability to interact with the nostrils of the patient and containing a channel 48 for receiving slidable injector 12. The injector 12 is able to move between the storage position (see figure 1)prior mutual the action of the input unit 18 with the nostrils of the patient, and the position of the interaction (see figure 4), respectively, for interaction input unit 18 with the nostrils of the patient. However, after the initial interaction input unit 18 with the nostrils of the patient, the injector 12 is desirable to translate, at least for a while in the storage position (see figure 3)until it is intentionally moved to the position of the interaction (see figure 4) under the guidance of the user. In some embodiments, the position of interaction of the injector 12 is in the middle and/or lower ONG. In other embodiments, the position of interaction of the injector 12 is in the middle, below and behind ONG, which is best shown in Figure 4.

As used here, the phrase "storage position" and "position interaction, each, aim to cover many of the provisions within the selected range. For example, in some embodiments, the degree to which the injector 12 is introduced into the first nostril of the patient (e.g., child), will differ from the extent to which the injector 12 is introduced into the second nostril of the patient (e.g., adult males). Despite this, the phrase "position of interaction aims to cover variants of the exact position of the injector 12 inside the nostrils, any of which is properly regarded as secondary and/or back and/or lower relative to the NG. In some embodiments, the injector 12 is not able to slide inside the input unit 18, but rather is fixed in a predetermined position in order to be in the middle and/or lower ONG after the interaction input unit 18 with the nostrils of the patient. In other embodiments, the injector 12 is not able to slide inside the input unit 18, but rather is fixed in a predetermined position in order to be in the middle, behind and below ONG after the interaction input unit 18 with the nostrils of the patient.

The injector 12 includes a tubular section 24 (so-called tube-Cobra, named for the ability to expand), which includes a channel 22 extending from the first end 29 to the second end 30 and is designed in such a way that it was administered medication. In some embodiments, the tubular section 24 has an external diameter of approximately 5 mm, and the channel having an inner diameter of approximately 2 mm throughout this description, the sizes and distances, such as these diameters should just strictly be considered as a demo and in no way is limited and/or fixed. There are significant differences in the sizes and distances referred to in this description that will be clear to the specialist.

In some embodiments, the second end 30 of the injector 12 includes a nozzle 28, have th nozzles 34, in which is situated one or a number of holes 36, is configured to spray the medication up and/or sideways, and/or forward to ONG. In some embodiments, the nozzle 28 is configured to spray the medication sideways and/or up towards ONG, and in other embodiments, the nozzle 28 is configured to spray the medication sideways, upwards and forward towards ONG.

In some embodiments, the nozzle 28 creates an angle upward from the second end 30 of the injector 12. In some embodiments, the nozzle 28 is held in the side, front and top directions angle, comprising from about 45° to about 60° to create the possibility of adaptation to the anatomy of different patients, in which ONG is on the side of the cavity behind the middle turbinate. In some embodiments, the nozzle 28 has a length in the range from about 2 mm to about 5 mm, In some embodiments, the injector 12 is made so that it can be configured handedness, for example, in some embodiments, the injector 12 is designed to interact with the left nostril of the patient, while in other embodiments, the injector 12 is designed to interact with the right nostril of the patient (in this case the left-hand path of the injector in General complements con is ur right injector).

The input device 18 may be directed into the nostril to create a horizontal path essentially parallel to the bottom of the nasal cavity or the base of the nose, thus, the input device 18 is held at the bottom of the nasal cavity at the position of the median relative to the lower nasal sink. This function is self-input unit 18 facilitates fast and accurate use of the device by the patient without the need to resort to the guidance of medical personnel. In some embodiments, the input device 18 creates a long path length between about 1.5 cm to about 2 cm into the nostril. After input unit 18 mounted steadily in the nose, the tip of the nose is usually directed upwards. The tubular section 24 of the injector 12 may then be partially or fully retracted before the end of the nostrils. In order to adapt to the slightly curved shape of the internal anatomy of the nose, the channel 48 in which is located a tubular section 24, may be slightly curved in the direction corresponding to the nostrils at from about 5 to about 20 degrees. After the tubular section 24 is installed in the desired position, the medication can then be submitted to ONG through the nozzle 28 to achieve the desired blocking effect ONG. In some embodiments, the device 10 is provided with an additional secure rigid support DL the restrictions continue for advancement in the nostril of the injector 12.

As clearly shown in figures 1, 3 and 4, the input device 18 includes a first section 44 and a second section 38. In some embodiments, the cross-sectional area of the first section 44 is greater than the cross-sectional area of the second segment 38. In some embodiments, the first section 44 generally concave and has a loop 46 is designed to replicate the shape of the inner part of the nostrils and, essentially, to meet her. In some embodiments, the narrow second section 38 has a rounded convex section 39 and the back side 40, having an essentially flat surface 42. The channel 48 of the input unit 18 receives is made slidable tubular section 24 of the injector 12 and in some embodiments it has a diameter ranging from about 6 mm to about 7 mm In some embodiments, the second section 38 of the input unit 18 includes interacting with nostrils the end, which stretches from about 1 cm to about 3 see In some embodiments, the first section 44 of the input unit 18 is stretched from about 2 cm to about 3 see In some embodiments, the input device 18 is designed so as to be able to configure handedness, for example, in some embodiments, the input device 18 is designed to interact with the left nostril of the patient, while in other embodiments, the input device 18 is made is so to interact with the right nostril of the patient (in this case the left-hand path input unit generally complements the contour of the right-hand input devices).

In some embodiments, the device 10 further includes a container 14, which is connected with the first end 29 and the channel 22 of the injector 12, which is designed with the ability to hold a medicine 16 (e.g., anesthetic). In some embodiments, as shown in figures 1, 3 and 4, the container 14 is attached to the rod 26 having a bottom section 31, which in some embodiments has an outer diameter essentially the same as the tubular section 24. The lower section 31 may be pulled in an outward direction, and/or up and/or angle from the first end 29 of the injector 12 and in some embodiments to connect with the upper section 32 having a larger diameter, is designed to accommodate the exhaust pipe 33 of the container 14. Similarly, the lower section 31 of the upper section 32 may be pulled in an outward direction, and/or up and/or angle.

In some embodiments, the container 14 is operatively connected, mounted or otherwise attached to the upper section 32 of the rod and a fully or partially filled with medication 16. After the container 14 is shown in communication with the channel 22 of the injector 12, the medication 16 may be filed by the tubular section 4 and released through one or more apertures 36 of the nozzle 28. The container 14 may be made of plastic, metal or the like and may be amenable to compression (compressed) and/or pressure to facilitate delivery of the drug into the channel 22. In some embodiments, the container 14 is replaced with the input hole (not shown) so that the drug could be introduced through an inlet opening in the upper section 32 using the device introduction, such as a syringe.

In some embodiments, the device 10 further includes an arm 20 connected to the rear section of the input unit 18 in the immediate vicinity of the first section 44. The handle 20 includes an upward groove 50, which creates the (channel) 52, is designed to accommodate and together with the channel 48 of the input unit 18 to be able to take slidable tubular section 24 of the injector 12. In some embodiments, the guide 52 has a depth or width ranging from about 6 mm to about 7 mm, the Handle 20 is made with the possibility of movement toward the face of the patient so that the reverse movement of the handle 20 led input unit 18 in the interaction with the nostrils of the patient.

The injector 12, the input device 18 and the handle 20 may be made of any materials, including, but not limited to, flexible, rigid or semi-rigid floor is dimensional materials (e.g., plastics, rubber etc), metals and their alloys and the like, and combinations thereof. In some embodiments, the injector 12 is of a flexible plastic, the input device 18 is elastomeric and/or elastic plastic or rubber and the handle 20 is made of plastic. In some embodiments, one or more injector 12, the input device 18 and the handle 20 are made of such material that they could perform a disposable and/or biodegradable.

While the exemplary device 10, described above, may be used to deliver the drug to the upward and/or sideways, and/or toward the primary nebnom the ganglion of the patient, in accordance with the principles set forth in the present description, alternative structures can equally well be used for the implementation of such delivery in the same way.

Solely as an example, the discharge cone having a curved section at one end, designed to be introduced into the nostril of the patient, similar to angle the nozzle 28 located at the second end 30 of the injector 12 may be placed within the essentially cylindrical (for example, having the form of a handle or cigars). The discharge cone can be made of flexible or semi-rigid material (e.g. plastic) so that he could keep what I essentially, linear or Pisogne position when in the storage position inside the case, but it's easy to take a curved shape, being extended from the housing to align the position of the interaction. In such a device, one or more inner surface of the outer case is designed for straightening or suspend, in whole or in part, given the curvature of the discharge cone until the moment when the discharge cone will be placed in the position of the interaction, after which the curvature of the cone is restored. In some embodiments, at least one site of injection cone (e.g., the end that is designed to release the medication), if necessary, can be extensible (for example, when air, oxygen, and/or other gases, and/or medications pass through the cone under pressure).

By applying one or more additional index mark (marking) on the cylindrical body described above, the user can easily determine the direction of curvature of the discharge cone mounted within, for example, by turning the chassis around, and education arc of 360°, the user can select any desired spray direction for delivery of drug at the discharge cone. A simple rotation of the housing, the spray direction can postopen is subject to change on a continuous arc from 0° to 360°, inclusive. In the development of one end of the housing may be provided with end Luera made with the possibility to interact with the syringe containing the medication. Alternatively, an end of the housing, is designed so that it remains on the outside of the nostrils, can be provided with a partition or a similar membrane through which the drug can be introduced into the discharge cone in it.

Many other modifications of the delivery devices described herein, as well as alternative structures are also provided for use in so far as they simply allow delivery of the drug up and/or sideways, and/or toward the primary nebnom the ganglion of the patient in accordance with this technology. As an example, a plot device intended for insertion into a nostril of the patient (for example, the area of the injector 12, described above)may be made of any therapeutically acceptable plastic material (for example, plastics, metals, metal alloys and the like)capable of receiving and maintaining the desired shape during use (for example, to increase or decrease the curvature of the angled nozzle 28 that is installed on the second end 30 of the injector 12). This feature may be desirable, for example, when a doctor wants to fine-tune the geometry of the device to use it is on the patient in the clinic.

Method of relieving pain in a patient in accordance with the present teachings includes delivery of drug to the upward and/or sideways, and/or forward the principle-nebnom the ganglion of the patient using the device described here. In some embodiments, the drug is served on the side and/or up towards ONG. In other embodiments, the drug is served sideways, upwards and forward towards ONG.

In some embodiments, the method of relieving pain in a patient includes (a) the input of the injector 12 through a nasal passage of the patient in the region, essentially located in the middle of and/or behind and/or below ONG patient; and (b) delivery of medication from the injector 12 upward and/or sideways, and/or forward to ONG. In some embodiments, the injector 12 is inserted through the nasal passage of the patient in the region, essentially located in the middle and/or lower ONG, while in other embodiments, the injector 12 is injected into the area, essentially, in the middle, below and behind ONG. In some embodiments, the drug is served sideways and/or up towards ONG, while in other embodiments, the drug is served sideways, upwards and forward towards the ONG. In some embodiments, the injector 12 has a second end 30 provided with one or more holes 36, through which the medication is sprayed toward ONG.

In some embodiments, injectors by the 12 sets slidable on the input device 18, as described above, and the method further includes (C) the interaction of the input unit 18 with the nostrils of the patient so that a portion of the nose of the patient was raised after the interaction with the input device 18; and (d) slippage of the injector 12 from the storage position to the position of the interaction after the input device 18 enters into interaction with the nostrils. As described above, the position of interaction of the injector 12 is located between and/or behind and/or below ONG, middle and/or lower in some embodiments, and in the middle, below and behind the others. In some embodiments, the drug is introduced into the container 14, is attached to and is connected with the injector 12, as described above, and the method further includes (e) compression of the container 14 containing the medication, the purpose of dispersion of drug in the direction of ONG.

In some embodiments, the method includes pushing the input unit 18 firmly and comfortably in the nostril to lift the nose of the patient to the location of the nozzles 28 of the injector 12 in proximity to ONG, the sliding tube section 24 of the injector 12 through the channel 48 of the input unit 18 and/or the sliding tube section 24 of the injector 12 through path 52 of the handle 20.

All kinds of drugs suitable for delivery to or near ONG proposes to use in accordance with the present position is tions. The physical state of the drug may include, but not limited to, liquid, solid, semi-solid substances, suspensions, powders, pastes, gels, etc. and combinations thereof. In some embodiments, the drug contains an anesthetic.

Anesthetics that can be used in accordance with the options described here include, but are not limited to, ambulan, amalasan, amylocaine, benoxinate, ethoxyquin, mefenamic, butagain, butamben, butanilicaine, boatmen, butokukan, kartikay, cocaethylene, cocaine, cyclomethycaine, dibucaine, dimethicon, dimethocaine, diperodon, dyclonine, ecgonidine, akognon, the ethyl aminobenzoate, ethyl chloride, etidocaine, P-Aucoin, Euphrosine, finallen, tomochin, hexylcaine, hydroxyprolin, hydroxytyramine, isobutyl p-aminobenzoate, laurencin mesilat, lauaxeta, lidocaine, meperidine, mepivacain, marilyin, metabolisation, methyl chloride, mortician, Narain, octgain, ortolan, oxethazaine, paradoxical, penagain, phenol, and pipecoloxylidide, piperocaine, pyridoxin, polidocanol, pramoxine, Samaritan, prilocain, proparacaine, proparacaine, propipocaine, propoxycaine, pseudococaine, procain, quinine urea(quinine), resochin, ropivacaine, salicyl-alcohol, tetracaine, Tolkein, trimekain, veratridine, salamin, etc. and their combinations, as well as their optical and/or Stere the isomers and their salts, used in pharmacology.

In some embodiments, the drug includes an anesthetic selected from the group which consists of benzocaine, tetracaine, ropivacaine, lidocaine, water, saline, and combinations thereof. In some embodiments, the drug comprises water and/or saline solution, having a temperature lower than about 10°C., and in other embodiments less than about 5°C. In some embodiments, the drug includes a combination consisting of benzocaine, tetracaine and ropivacaine. In some embodiments, the drug comprises an anesthetic, comprising about 14% of benzocaine, about 2% of tetracaine and about 1% of ropivacaine of the total weight of anesthetic.

In some embodiments, the mixture of benzocaine, tetracaine and ropivacaine is used to achieve rapid impact ONG blockade, as well as long-term effects of anesthesia, thus reducing the need for repeated applications of drugs and minimize any potential complications, dose-dependent and/or side effects. Benzocaine, which is quite effective when the local application and its toxic dose of more than about 200 mg, has a start time of about 30 seconds and a duration of from about one half to about one hour. Benzocaine provides almost immediate beginning pain and can provide the enhance the absorption of other local anesthetics when mixed with them. Ropivacaine, whose toxic dose of 175 mg, usually begins slowly, but it lasts from about two to about six hours. Ropivacaine provides enhanced conduction anesthesia and prolonged anesthesia. Tetracaine is a very strong local anesthetic with a rapid onset and duration from half an hour to one hour. when mixing tetracaine with ropivacaine, duration of pain greater than 6 hours.

In some embodiments, the drug used in accordance with this invention, is fed into the container 14 (shown in figures 1, 3 and 4) in the form of compressed or aerosolizing mixture. The drug also contains preservatives, liquid media and/or other inert ingredients and additives that will be clear to the specialist.

The amount of medication supplied in accordance with this invention can be easily determined by the expert and will vary depending on factors such as quality and/or concentration of drug, the patient's age, condition and/or sensitivity to the drug, etc. In some embodiments, the anesthetic dosage is in the range from about 0.1 CC (critical concentration) to about 1.0 CC. In some embodiments, the anesthetic dosage is about 0.5 CC.

Ways and make the tion, described herein are intended for use in the treatment of all types of States, for which it is desirable introduction of the drug up and/or sideways, and/or towards ONG patient. Exemplary conditions that can be treated in this way include, but are not limited to, primary palatal neuralgia, trigeminal neuralgia, including glossopharyngeal neuralgia, migraine with or without aura, headaches, pressure headaches, including chronic headaches, paroxysmal hemicrania, Verkhneportovaya neuralgia, atypical facial pain, ganglionic ciliary site, vasomotor rhinitis, depression, fibromyalgia, etc. and their combinations.

Local application of the drug to human tissues for system introduction pharmaceutically active agent usually involves the use of easily absorbed through the skin and/or through the mucous membrane pastes, creams, liquids, solids, semi-solid substances, etc. However, systemic introduction of pharmaceutically active agents through local application is difficult due to the complexity of penetration of the agent through the tissue, which are coated with an agent to contact the blood vessels, where the agent can then be absorbed in to system administration. Thus, to solve this problem, the method and device, described here could contribute to increased permeability of the blood-brain barrier when applying any medication.

Convection procedures create ONG blockade used to treat a wide range of diseases, and the described methods and devices are provided for use in the treatment of all of them. Typical of the disease include pain and/or discomfort associated with mythicism spasm, vascular spasm, neuralgia, reflex sympathetic dystrophy, chronic low back pain of various etiologies (e.g., muscle, disc, arthritis, and others), pain in the external perevalnom the cartilage of the mandibular dental pain, glossodynia, pain in the ear (in cases of inflammation Evstafieva pipes and damage to the middle ear, the secondary ear pain caused by cancer of the larynx, the pain caused laryngeal TB, spasm of the face and upper respiratory tract, syphilitic headache, headache with malaria, paroxysmal headache, atrial scotoma, dysmenorrhea, intercostal pain (neuralgia), stomach pain, nausea and diarrhea, myalgia of neck muscles, sciatica, maxillary neuralgia, sensory facial neuralgia, pain, upper teeth, pain associated with tooth extraction, a sensation of a foreign body in the throat, the permanent itching, external ear canal, zoster ear shingles, impaired taste perception, atypical facial pain, trigeminal neuralgia, cervical arthritis, dysfunctional-muscle pain-facial syndrome, peripheral neuropathy, neuralgia after shingles, fractures associated with osteoporosis, lumbar-sacral tension (voltage), and various other arthritic conditions, etc. and their combinations, but are not limited to. Further definitions that are described here are devices and methods include control of sudden fits of anger, withdrawal depression, etc., but are not limited to.

The term "set" refers to a set of materials that are used in the application of the method in accordance with this invention. Such kits may include one or more device and/or its elements, including, but not limited to, the exemplary device described above, and may further include one or more medication to use with them, including, but not limited to, one or more anesthetic mentioned above.

In some embodiments, the kit includes injector and/or input device, each of which is designed to interact with the left nostril of the patient. In some embodiments, the kit includes injector and/or vodnewscast, designed to interact with the right nostril of the patient. In some embodiments, the kit includes injector and the input device, is designed to cooperate with the left nostril of the patient and to the right. Additionally can be fitted with interchangeable arm to attach either to the right or to the left-hand input device. In other embodiments, the handle itself is configured handedness, and a separate handle may be provided for each driver input unit and left-hand input devices.

In some embodiments, it is assumed the presence of the device in a fully assembled state, while in other embodiments, the Assembly device is required. In some embodiments, the device is provided with a set that includes the discharge cone having a curved section at one of its ends, is made for insertion into a nostril of the patient, while the discharge cone is located inside an essentially cylindrical (for example, having the form of a handle or cigars), for example, as described above. In some embodiments, one or many elements of the device are disposable and optionally biodegradable.

Drug included in this kit may contain disreagard or multiple reagents. Sample used medications in accordance with the present technology include, but are not limited to those mentioned above. Medicines can be represented in compressed form in one or in separate containers, depending on their cross-reactivity and stability and, in liquid or dried form they are in. The number and proportion of all reagents provided in the kit, can be chosen in such a way as to provide optimum results for a particular application.

The medications included in the set can be supplied in all types of containers so that the intensity of the actions of the various components, essentially, remained, while the components themselves are slightly absorbed or changed as a result of interaction with the material of the container. Acceptable containers include, but are not limited to, vials, bottles, tubes, vials, flasks, syringes, bags and envelopes (for example, covered with a film (foil)and the like, the Containers can be made from any appropriate material, including, but not limited to, glass, organic polymers (e.g. polycarbonate, polystyrene, polyethylene and the like), ceramics, metal (e.g. aluminum), metal alloys (e.g. steel), cork, etc. Additionally, the containers can have one or more sterilin is the first available port (for example, for access through the needle), for example, can be represented by a partition. Preferred materials for walls include rubber and polymers, including, but not limited to, for example, poly-tetrafluoroethylene type, which is sold under the trade name TEFLON F. DuPont (Wilmington, Del.). Additional containers may contain two or more compartments separated by partitions or diaphragms, which can be removed by order of mixing of the components.

Kits in accordance with the present invention can also be delivered with other elements known in the art and/or which may be desirable from a commercial or user point of view, for example, empty syringes, tubing, gauze, pads, disinfectants, cleaning solutions, how to create ONG blockade and/or Assembly, use and/or cleaning device, etc. and their combinations.

In some embodiments, the instructions may be attached to one or more devices and/or containers (e.g. vials) or to a larger container, which is wrapped one or more element of the set for transportation. Instructions may also be submitted as separate attachments, called the advertising insert in the package. Instruction material accompanying sets, m is able to be printed (for example, on paper) and/or submitted on electronic media (e.g. floppy disk, CD-ROM, DVD-ROM, zip disk, in the form of videos, audio recordings, and so on). Alternatively, the instructions may be in the form of the user's guide on the web site (for example, specified by the manufacturer or distributor of the set) and/or via e-mail.

The following examples show the features described here are devices and methods and are given only as illustrative material. They are not intended to limit the claims of the invention or its equivalents.

EXAMPLES 1-30

The above-described devices and/or methods have been applied for the treatment of 30 patients suffering from chronic headaches, such as paroxysmal headaches and headaches caused by pressure. The results of this testing surprising and unexpected. To illustrate the result of applying the above methods was, at least, decrease pain by 90% and 100% efficiency ONG blockade in 100% of patients. The pain began to decrease over the period of time of about 30 seconds to about 60 seconds, and the duration ranged from about 4 to about 24 hours. Each ONG blockade was performed using only 0.5 CC or less a mixture of anesthetics include benzocaine, tetracaine and ropivacaine in the volume of the x, described above. Have at least 10 patients the length of time the treatment of pain, in accordance with the present technology, lasted up to 24 hours. In General, it was agreed extremely effective control of a headache. Patients were able to return to work and avoid the use of toxic drugs in almost 100% of cases.

Described here are devices and methods are applicable to most patients over the age of 15 years in 95% of the population regardless of the growth of the patient's weight, sex, and race. In addition, although currently it is believed that these devices and methods will primarily be used for the treatment of humans, these devices and methods can also be used to treat all kinds of patients (not people). Any patient with nostrils (for example, other mammals, such as primates, dogs, cats, pigs, horses, cows, etc., and not mammals), can also be subjected to treatment (e.g., veterinarian) in accordance with the principles set forth herein.

In General, the described devices and methods provide safer and more effective aid in the treatment of pain associated with headaches, facial pain and other Devices and methods are economical and can easily be applied to patients by qualified nurses, as well as by the patients without guidance from the parties the health worker to provide reliable and replicable delivery of medication to the target point. In some embodiments described here are devices and methods can be used by the patient twice per hour or as needed.

When operating the auxiliary handle 20 of the device 10 described herein, can move toward the face of the patient until such time as the input device 18 will not be included and will not settle firmly and comfortably in the nostril of the patient to raise the nose of the patient so that he was facing up and slightly back. After that, the injector 12 may be pushed back toward the nose of the patient to move the tubular section 24 and the nozzle 28 in the rear direction while the nozzle 28 will be located between and/or behind and/or directed to ONG, middle, and/or directed forward in some embodiments, and in the middle, directed forward and behind in others. After this medication, such as an anesthetic, can be injection and sprayed through the holes 36 of the nozzle 28 upward and/or sideways, and/or towards ONG with the aim of relieving pain, sideways and/or up in some ways and sideways, up and forward in other ways. When appropriate anesthetic is sprayed on ONG, can be achieved fast and long-lasting vasoconstriction (narrowing) of blood vessels that relate to the same side of the head or brain, resulting in I which is effective pain management.

Provides a detailed description and accompanying drawings are only for explanation and example and are not intended to limit the invention as described in the accompanying claims. Many variants of the present invention will be applied by specialists in this field without departing from the essence of the present invention, which is set out in the accompanying claims.

1. The way to relieve pain associated with headaches and/or facial pain in a patient, including:
the introduction of the injector through a nasal passage of the patient in the region essentially middle and/or back and/or lower relative to the main-Palatine ganglion of the patient; and
delivery of medication from the injector up and/or sideways, and/or toward the primary nebnom the ganglion.

2. The method according to claim 1, in which the region is essentially the middle and lower against major nebnom the ganglion.

3. The method according to claim 1, in which the region is essentially the middle, bottom and back towards the main-nebnom the ganglion.

4. The method according to claim 1, in which the drug is supplied to the side and up towards the main-nebnom the ganglion.

5. The method according to claim 1, in which the drug is served sideways, upwards and forward towards the main-nebnom the ganglion.

6. The method according to claim 1, in which the region is essentially the middle, bottom and back against the main-nebnom the ganglion and in which the drug is supplied to the side, upward and forward toward the main-nebnom the ganglion.

7. The method according to claim 1, in which pain include headache, facial pain, or combinations thereof.

8. The method according to claim 1, wherein the injector includes a first end, made to stay outside nasal passage and a second end, is made to enter into the nasal passage.

9. The method according to claim 8, in which the drug is served from a second end of the injector.

10. The method according to claim 9, in which the second end contains one or multiple holes through which the medication is sprayed toward the major nebnom the ganglion.

11. The method according to claim 10, in which a medicine contains an anesthetic.

12. The method according to claim 11, in which the anesthetic selected from the group consisting of benzocaine, tetracaine, ropivacaine, lidocaine and their combinations.

13. The method according to claim 11, in which the anesthetic contains benzocaine, tetracaine and ropivacaine.

14. The method according to item 13, in which the anesthetic contains about 14% benzocaine, about 2% of tetracaine and about 1% of ropivacaine by weight, of the total weight of anesthetic.

15. The method according to claim 1, in which the injector slidable taken into the input unit and in which the introduction of the injector includes:
the interaction of the input unit from the nostrils of the patient so that the portion of the nose of the patient rises when interacting with an introductory device; and a slide and is of rectora of the storage positions in the position of the interaction after as an introductory device interacts with the nostrils, in which the position of interaction of the injector is in the middle, and/or behind and/or below the primary nebnom the ganglion.

16. The method according to item 15, in which the position of interaction of the injector is in the middle and inferior to the primary nebnom the ganglion.

17. The method according to item 15, in which the position of interaction of the injector is in the middle, below and behind with respect to the main-nebnom the ganglion.

18. Device for delivery of medication to a patient in need this, containing:
injector containing the first end, made to stay outside nasal passage of a patient, and a second end, is made to enter into the nasal passage of the patient, and the second end of the injector contains one or multiple holes made for spraying the medication up and/or sideways, and/or toward the primary nebnom the ganglion, and
input unit, designed to interact with the nostrils of the patient and containing a passage for receiving the injector.

19. Device for delivery of medication to a patient by p, in which:
the injector is configured to move between a storage position prior to the interaction, and the position of the interaction corresponding to the interactions, and
W is the position of the interaction is in the middle, and/or behind and/or below a relatively basic-Palatine ganglion.

20. Device for delivery of medication to a patient according to claim 19, in which the position of the interaction is in the middle and below basic-Palatine ganglion.

21. Device for delivery of medication to a patient according to claim 19, in which the position of the interaction is in the middle, below and behind the main-Palatine ganglion.

22. The device according to p in which the drug is sprayed to the side and up towards the main-nebnom the ganglion.

23. The device according to p in which the drug is sprayed sideways, upwards and forward towards the main-nebnom the ganglion.

24. The device according to p, in which the position of the interaction is in the middle, below and behind the main-Palatine ganglion and in which the medication is sprayed sideways, upwards and forward towards the main-nebnom the ganglion.

25. The device according to claim 19, in which the injector includes a channel that extends from the first end to the second end and is made to receive the medication.

26. The device according A.25, optionally containing a channel connected with the first end of the injector, in which the channel is designed to receive a syringe containing the medication.

27. The device according to p, optionally containing container is in communication with the first end of the injector, while the container is made to the contents of the medication.

<> 28. The device according to item 27, in which the container is made of compressible so that the medication in the container is moved into the channel as a result of compression.

29. The device according to p, in which the container is under pressure.

30. The device according to p, in which the input device includes a first section and a second section in which the cross-sectional area of the first area bigger than the area of the cross section of the second section.

31. The device according to item 30, in which the first section has the following form, which is made to correspond to the inner shape of the nostrils.

32. The device according to p, in which the second section contains a rounded convex section and essentially flat reverse side.

33. The device according to p, optionally containing a handle connected to an input device.

34. The device according to p, in which the handle includes a guiding device for receiving channel input devices.

35. The device according to clause 34, in which the arm is made to move toward the face of the patient, so that movement of the handle back led input device in communication with the nostrils of the patient.

36. The device according to p, in which the injector is made to communicate with the left nostril of the patient.

37. The device according to p, in which the input device is configured to communicate with left the nostrils of the patient.

38. The device according to p, in which the injector is made to communicate with the right nostril of the patient.

39. The device according to § 38, in which the input device is configured to interact with the right nostril of the patient.

40. The device according to p, which through interaction input unit with nostrils is provided a horizontal path essentially parallel to the base of a patient's nose in the medial position to the lower nasal shell patient.

41. The device according to p, in which the input device so designed as to be supported by the bottom of the nasal cavity of the patient.

42. How to use the device on p for delivery of medication to a patient, including:
the interaction of the input unit from the nostrils of the patient;
the movement of the injector in the position of the interaction; and
the dispersion of drug in the direction of the main-nebnom the ganglion through the nozzle at the second end of the injector.

43. The way to relieve pain associated with headaches, facial pain in a patient, including:
delivery of drug to the upward and/or sideways, and/or toward the primary nebnom the ganglion, using the device according to p.

44. The method according to item 43, in which the drug is supplied to the side and up towards the main-nebnom the ganglion.

45. The method according to item 43, in which the drug is delivered sideways, upwards and in the before towards major nebnom the ganglion.

46. The method according to item 43, in which the patient suffers from a condition selected from the group consisting of: basic-palatal neuralgia, trigeminal neuralgia, glossopharyngeal neuralgia, migraine, migraine with aura headache migraine without aura headache, headache caused by pressure, paroxysmal headache, chronic paroxysmal headache, the paroxysmal hemicrania, Verkhneportovaya neuralgia, facial pain, atypical facial pain, ganglionic ciliary site, vasomotor rhinitis, depression, fibromyalgia, and combinations thereof.

47. The method according to item 43, in which the result of the application of this method is the increased penetration of the drug through chemoenzymatically barrier.

48. The method according to item 43, in which pain is a headache, facial pain, or combinations thereof.

49. Device for delivery of medication to the needy in this patient, comprising:
injector containing the first end, made to stay outside nasal passage of a patient, a second end, is made to enter into the nasal passage of a patient, and a channel that extends from the first end to the second end and is made to accept a medicine, in which the second end of the injector contains one or multiple holes made for spraying drug up, WB is to and toward the primary nebnom the ganglion;
introductory device designed to interact with the nostrils of the patient and containing a passage for receiving the injector slidable, the first portion having a shape corresponding to the shape of the inside of the nostrils, and the second section containing rounded convex section and substantially flat back side, in which the cross-sectional area of the first section is greater than the cross-sectional area of the second segment; and
the handle is connected with the input unit and containing a guide made for the reception channel of the input unit;
when this arm is made to move toward the face of the patient, so that movement of the handle back led input device in communication with the nostrils of the patient;
this injector can be moved between the storage position prior to the interaction, and the position of the interaction corresponding to the interaction; and
in which the position of the interaction is in the middle, behind and below the main-nebnom the ganglion.



 

Same patents:

FIELD: chemistry.

SUBSTANCE: invention relates to a novel biologically active 2,6-dimethylanilide of N-cyclohexylpyrrolidine-2-carboxylic acid, having surface, infiltration and conduction anaesthesia activity, considerably better than bupivacaine and ropivacaine with the same or less toxicity.

EFFECT: improved compounds.

2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: what is presented is a pharmaceutical composition in the form of a spray for treating a damage by non-lethal irritants (e.g. pelargonic acid morpholide), containing pediphene in the following proportions, wt/volume %: pediphene hydrochloride 0.01-10.0; sodium chloride 0.1-10.0; water for injections up to 100 ml. What is shown is the efficacy of pediphene in compliance with the declared application ensured by the local anaesthetic effect of the drugs.

EFFECT: drug preparation has no allergenic and immunotoxic properties.

3 dwg, 40 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely anesthesiology, intensive therapy and endosurgery, and may be used in patients in need of endoscopic transpapillary intervention. That is ensured by an intravenous infusion therapy with crystalloid solutions in the amount of 800-1200 ml. An epidural space is punctured and catheterised at the level of Th VIII - Th IX with the catheter moved by 4-5 cm in the cranial direction. A local anaesthetic solution and Clopheline 100 mcg are introduced through the epidural catheter at the level of Th V - Th X 20 minutes before the endoscopic transpapillary intervention. It is followed by pre-medication enabled by introducing 0.1% atropine 0.5-1 ml and 0.5% relanium 1-2 ml, and the patient is wheeled into a catheterisation laboratory. After the endoscopic transpapillary intervention completed, the patient is transferred into an intensive therapy unit wherein prolonged epidural analgesia is enabled by introducing 0.5-1% lidocaine 10 ml into the epidural space every 4 hours. If observing no clinical manifestations of postoperative pancreatitis, the epidural catheter is removed, and the patient is transferred into a department of surgery for symptomatic treatment.

EFFECT: method enables preventing acute postoperative pancreatitis following such interventions due to action of a general mechanism of pathogenesis of the given pathology.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a pharmaceutical vaginal composition for reducing or relieving uterine dysrhythmia. The composition contains an antidysrhythmia drug in the concentration of 1 wt % to 12.5 wt % and a pharmaceutically acceptable carrier providing prolonged release. The carrier contains a bioadhesive, water-swellable, water-insoluble, cross-linked polycarboxylic acid polymer such as polycarbophil. The drug is specified in prilocaine, mepivacaine, bupivacaine, ropivacaine, ethidocaine, mexiletine, procainamide, moracizin, propaphenone and flecainide.

EFFECT: invention provides reducing or relieving uterine dysrhythmia with prolonged release of said drugs with creating adequate local concentrations and low blood concentrations.

9 cl, 33 ex

FIELD: medicine.

SUBSTANCE: after performing main stage of surgery, under visual control needle puncture is performed into retroperitoneum space of right iliac fossa perpendicularly to skin, 1 cm inward from anterior superior iliac spine. Needle is passed inward, downward and frontward to the depth 6-8 cm, sliding on internal surface of iliac bone. Conductor is introduced through needle lumen and polyethylene catheter, through which after the end of operation, after 4-6 and 10-12 hours introduced is naropin in dose 2.5 mg/ml in 0.9% sodium chloride solution, is installed.

EFFECT: method makes it possible to ensure adequate and safe anesthetics in post-operative period due to accuracy of introduction of anesthetic directly in the zone of surgery.

2 ex

FIELD: medicine.

SUBSTANCE: puncture point is anaesthetised by 0.5% bupivacaine. It is followed by puncture of a subdural space with the use of a spinal needle at the level of L3-4, L4-5 from a medial approach. A local anaesthetic is presented by hyperbaric 0.5% bupivacaine 0.8-1.2 ml. The patient is kept seating for 10 minutes.

EFFECT: method enables adequate anaesthesia with ensured maximum perineal myorelaxation combined with decreased drug-induced load on mother's and foetus's bodies.

1 ex

FIELD: medicine.

SUBSTANCE: spray composition contains, wt/vol %: lidocaine hydrochloride 1.0-10.0; benzethonium chloride 5.0·10-4 - 5.0·10-3; sodium chloride 0.1-10.0; water for injections to 100 ml.

EFFECT: use of the declared composition is effective for treating damages by non-lethal irritants.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely anaesthiology in ophthalmosurgery, and may be used in vitreoretinal surgeries, including those terminated by the stage of introducing silicone oil. For this purpose, 40-45 minutes before the operation, the retrobulbar introduction of a mixture of 2% lidocaine and 0.75% ropivacaine in proportions 1:1 in the amount of 4-5 ml is prescribed. It is followed by the intraoperative intravenous titration introduction of 0.01% nitroglycerine starting with 1 ml 1-2 minute before the introduction of silicone oil in response to a surgeon's signal. The nitroglycerine introduction is terminated when patient's systolic blood pressure becomes lower than the initial values by 10-20%.

EFFECT: method provides adequate anaesthesia combined with a reduced risk of developing complications due to blood pressure correction at the specific stage of surgery.

1 ex

FIELD: medicine.

SUBSTANCE: method involves the intramuscular introduction of the preparations Galavite 200 mcg/mouse and Lidocaine 8 mcg/kg of body weight once a day for three days running every 24 hours to experimental animals CBA line mice suffering a burning injury with underlying mycotic and bacterial infections accompanied by anti-infectious protection suppression.

EFFECT: invention enables creating a model of hospital strain formation which is applicable for studying the variations of the properties of opportunistic microorganisms to increasing virulence and antibiotic resistance.

2 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely neurology, orthopaedics, reflexotherapy, physiotherapy exercises, recreation therapy and is applicable in integrated treatment of myofascial pain accompanying spine osteochondrosis. Pain management procedures are followed by a complex of exercises with using the HUBER apparatus consisting of seven staticodynamic exercises aimed at strengthening and activation of muscles of upper limb girdle, greater pectoral muscle, pelvic floor muscles and gluteal muscles. It is combined with loading and coordination improvement of left broadest muscle of back, left obliques, left lumbar quadrate muscle. Upper shoulder anchors, broadest muscle of back and rhomboid muscle are relaxed, and postural muscles are coordinated. Lumbar spine muscles are relaxed. Tone in upper extremity and back muscles is strengthened. It is followed by making exercises for activation of muscles of upper limb girdle, pectoral muscles, pelvic floor muscles, gluteal muscles. Then, the exercises for strengthening of lumbar muscles for the purpose of improving the body position coordination, relaxation of back ground of femoral and hip muscles, strengthening of abdominal wall muscles.

EFFECT: method improves support ability of feet, normalises position of the centre of gravity, forms an optimum motor conditions.

3 ex, 7 dwg

Aerosol container // 2487730

FIELD: medicine.

SUBSTANCE: invention relates to medical equipment. What is disclosed is a spray system with a drug container. According to one of the versions, the present invention involves a drug container a wall thickness of which makes approximately 100 to 240 mcm, and which can contain a pin hole to release and disperse the drug.

EFFECT: invention provides producing simple and stable opening of the container and reliable production of multiple doses.

9 cl, 11 dwg

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine. An inhaler comprises a body which represents a drug container, a compressed gas jet nozzle and a fluid passage connected with the container and used to supply the drug directly to the jet to produce an aerosol drug. Additionally, the inhaler can comprise an inlet hole connected with the body and used to supply the aerosol to the patient, an entrapping passage used to entrap an respiratory flow from atmosphere and a control passage connected via a fluid medium with the fluid passage and used to supply a control gas into the fluid passage for prevent the drug from supplying directly to the jet. The control passage can contain a gas tube neighbouring the entrapping passage. The entrapped respiratory flow in the entrapping passage prevents substantially the control gas flow through the entrapping passage to finish control gas supply to the fluid passage.

EFFECT: group of inventions allows minimising a number of movable parts that simplifies manufacturing of the inhaler.

60 cl, 20 dwg

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine. Nebuliser contains case, containing reservoir for placement of medication; nozzle, located in case, for production of jet of compressed gas; canal for flowing medium, connected with reservoir for supply of medication directly into jet for obtaining medication aerosol; nebuliser output, connected with case for delivery of aerosol to patient; control canal, connected via flowing medium with canal for flowing medium for supply of control gas into canal for flowing medium for preventing supply of medication directly into jet. Nebuliser is provided with connected with control canal jet amplifier, made with possibility to regulate supply of control gas into control canal. Described are versions of nebuliser different in implementation of means of regulation of control gas supply. Described are versions of methods of nebulisation process control.

EFFECT: control of medication supply in accordance with patient's inhalation without application of movable elements.

86 cl, 14 dwg

The invention relates to medical equipment, namely, devices for generating aerosols during inhalation treatments

FIELD: chemistry.

SUBSTANCE: invention relates to a co-crystalline form of bicalutamide with 2-hydroxybenzamide with molar ratio of 1:1. The co-crystalline form has: an endothermic peak from 156°C to 160°C based on measurement data through differential scanning calorimetry (DSC analysis), peaks at 2θ(°) 3.16, 4.94, 5.66, 26.1 based on measuring X-ray diffraction of the monocrystal.

EFFECT: obtaining a novel co-crystalline form of bicalutamide with a high rate and level of solubility, which can be used as a pharmaceutical preparation for treating prostate cancer.

5 cl, 7 dwg, 2 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula I

or a pharmaceutically acceptable salt thereof, where R1 is H or R1 and R2 together with a nitrogen group can form where A, B, C and D are independently selected from a group consisting of CR1a and N; where at least one of A, B, C and D is CR1a; where R1a is selected from a group consisting of H, -ORi, -SRii, -S(O)Riii, -C(O)NRvRvi and CF3, where Ri is selected from a group consisting of methyl, ethyl, propyl, hydroxyethyl, hydroxypropyl, 2-oxo-2-phenylethyl, butyl, acetonitrile and benzyl; Rii, Riii and Riv denote methyl; Rv and Rvi are independently selected from a group consisting of H, methyl, ethyl, hydroxyethyl, hydroxypropyl, diethyalminoethyl, phenyl, pyridinyl, methoxyethyl, hydroxyethoxyethyl, benzyl, phenylethyl, 2-hydroxy-1-hydroxymethyl-2-phenylethyl and carbomoylethyl, or Rv and RVi together form morpholine or ethyl ester of piperazine; R2 is selected from a group consisting of phenyl, naphthyl, pyrazolyl and C1-C8alkylene phenyl; R3 is C1-C8alkylene; R4 is selected from a group consisting of H, C1-C8alkyl and -C=NH(NH2). The invention also relates to compounds of formulae I-A

I-B I-C

I-D I-E

values of radicals of which are given in the claim; a method of treating said pathological conditions, a pharmaceutical composition based on said compounds, a method of identifying a Trp-p8 agonist and specific compounds.

EFFECT: obtaining compounds which are useful as Trp-p8 modulators.

25 cl, 19 dwg, 8 tbl, 17 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a method for preparing fine pharmaceutical compositions of salbutamol. The declared method consists in quick cooling of an initial solution of salbutamol and glycine or salbutamol and lactose monohydrate in a solvent of tetrahydrofuran (THF) and water, wherein the THF concentration makes 5-25 wt % by spraying the initial solution into a container with liquid nitrogen. The prepared mixture of solid phases is cleaned from the solvents by sublimation in a liquid nitrogen flow with continued pumping by progressive temperature increase: -196°C to -5°C with pressure decrease 100 Pa to less than 2 Pa, then to +30°C, and kept for 2 hours at specified temperature and pressure increase to 1 atm. The salbutamol concentration in the initial solution makes 4 wt % per weight of the solvent of THF and water, while the glycine and lactose monohydrate concentration makes up to 10 wt % per weight of the solvent of THF and water.

EFFECT: invention provides preparing the fine pharmaceutical compositions of salbutamol characterised by bulk density of 0,3-0,45 g/cm3 and high surface unit area, applicable in inhalation therapy.

19 dwg, 7 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular, to surgery and can be applied for prolonged anesthetisation in early post operational period of patients with haemorrhoids of III-IV stage. For this purpose 1% solution of morphine in dose 0.1 ml per 10 kg of weight is introduced one time per day in peridural space between vertebras L2-L3 , or L3-L4 through catheter. Said quantity is diluted with 6 ml of physiological solution. Such volume of narcotic medicine ensures effective anesthetisation within 18-20 hours. After that, after said time expiry, 6.0 ml of 2% solution of lidocaine are additionally introduced, which ensures anesthetisation effect within 4 hours. Claimed procedure is repeated on 2 and 3 day in the same succession.

EFFECT: invention ensures prolonged anesthetisation in early post operational period within 3 days, due to reduction of introduced narcotic analgesic (morphine) dose, which makes it possible to reduce probability of development of addiction and development of side effects in patients.

3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, more specifically to physiotherapy, otorhinolaryngology, audiology, rehabilitation medicine, and may be used for the physiotherapeutic body exposure in the diseases developed in cerebral and cervical human tissues and organs, such as perceptive hearing loss, siagonantritis, eustachitis, temporomandibular dysfunctional pain syndrome, odontogenous or rhinogenous trifacial neuralgia, Bell's palsy etc. For this purpose, a concha of auricle is exposed to electric current by introducing an electrode into an ear to contact a cavity and cup of concha tightly. Besides, the above are exposed to electric current through an electrode placed into a nasal passage. The electrodes are wrapped in a wet tissue made of a non-woven material with surface density 160-180 g/m2 containing a polymer layer of sodium alginate containing a drug preparation or a mixture thereof. The exposure is generated by direct electric current with its intensity to be gradually increased from 1 to 5 mA. The procedures are sequential at first from one side, and then from the other side. The exposure time makes 10-15 minutes from each side. The therapeutic course is 8-12 daily procedures.

EFFECT: appropriate prescription of the drug preparations enables the method providing the evident analgesic and anti-inflammatory action, activation of the tissue immune processes, improved innervation within the exposure region, recovered locomotor function of the temporomandibular joint and masticatory muscles, higher contractive activity of the muscles of expression, reduced development of any negative responses and complications ensured by the combined action of direct electric current and prolonged action of the pharmacological preparations in the presented tissues.

3 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine and aims at conducting the endoscopic hemostasis in gastric-duodenal hemorrhages. For the purpose of conducting the hemostasis, the capillary hemostasis liquid "Hemostab" is used and accompanied by the injection compression infiltration of paravasal and periulcerous regions. "Hemostab" is introduced within a hemorrhage point that is followed by the argon-plasma coagulation.

EFFECT: using the declared group of inventions is effective for the hemostasis in gastric-duodenal hemorrhages; it has the positive local effect on the clinical course of the pathological process, reduces the length of recovery of the defects caused the hemorrhage with no toxicity of the above preparation and no allergies.

1 ex, 3 dwg, 6 cl

Up!